Market Overview

The Alpelisib market is predicted to develop at a compound annual growth rate (CAGR) of XX% from 2024 to 2034, when it is projected to reach USD XX Million, based on an average growth pattern. The market is estimated to reach a value of USD XX Million in 2024.

SOURCE: We Market Research

Alebrisib is one medication that is used to treat several diseases, most notably advanced breast cancer. The substance originates from a class of drugs known as PI3K inhibitors, which work by blocking a specific pathway that promotes the growth and spread of cancer cells. Alpelisib, a phospholipase 3-kinase (PI3K) inhibitor, exhibits potent anticancer properties. It works by selectively inhibiting the catalytic subunit of PI3K, class I PI3K p110α, a lipid kinase implicated in numerous biological processes like survival, proliferation, differentiation, and metabolism. This enzyme, which appears to be hyperactivated due to mutations at a rate of about 30% in human malignancies, is the precise target of the drug alepelisib.

The FDA approved alpelisib on May 24, 2019. The FDA approved the use of alepelisib in April 2022 for the treatment of adults and children with PIK3CA-Related Overgrowth Spectrum (PROS) who need systemic therapy. The global market for aleplisib is being driven by advancements in precision medicine, an increasing number of cancer cases worldwide, and an increasing frequency of cancers with PIK3CA mutations. The positive clinical efficacy and safety properties of combination medications enable their use. Increasing access to healthcare and funding for oncology research are two further reasons propelling market rise. Alepelisib's adoption and positioning as a crucial element of targeted therapy for specific cancer types, such breast cancer, mostly relies on commercial expansion strategies and regulatory clearances. 

Market Scope

Alpelisib Industry: Dynamics & Restrains

 We Market Research: Alpelisib Dashboard

Our marketing platform offers a comprehensive dashboard that provides clients with valuable insights into market trends over the years. Included below is a sample image of our dashboard, and specific PDF logins will be furnished to grant access to this insightful tool.

Alpelisib Segmentation

Market- By Product Type Analysis

By Product Type, the Alpelisib Market is Categories into Piqray, Vijoyce. The Piqray segment accounts for the largest share of around 92% in 2024.

The drug created by Novartis, known by the brand name Piqray (Alpelisib), is well-known and used to treat metastatic breast cancer with PIK3CA mutations that is hormone receptor (HR)-positive but HER2-negative.

The following segments are part of an in-depth analysis of the global Alpelisib market:

Alpelisib Industry: Regional Analysis

North America Market Forecast

North America dominate the Alpelisib Market with the highest revenue generating market with share of more than 48%. Strong R&D spending, a high rate of breast cancer, and a sophisticated healthcare system are the primary drivers of the Alpelisib market in North America, particularly in the US. Advantageous reimbursement practices and early uptake of novel medications also contribute to market growth.

Europe Market Statistics

Europe is the second largest market in Alpelisib market. The growing awareness of personalized medications and precision medicine is helping Alpelisib's market share in Europe. In countries like Germany, France, and the UK, market expansion is facilitated by substantial government programs that pay for cancer treatment and large healthcare expenditures.

Asia Pacific Market Forecasts

Asia Pacific is expected to be the fastest-growing regional segment of the Alpelisib market during the forecast period. The Asia Pacific area is witnessing rapid market growth because of an extensive patient pool, increasing disposable income, and better healthcare facilities. Important regions like China and India are seeing expansion due to rising cancer incidence rates and improved access to cutting-edge therapies.

Key Market Players

The Alpelisib Market is dominated by a few large companies, such as

·         Novartis AG

·         Other

1.      Global Alpelisib Market Introduction and Market Overview

1.1.    Objectives of the Study

1.2.    Global Alpelisib Market Scope and Market Estimation

1.2.1. Global Alpelisib Overall Market Size, Revenue (US$ Mn), Market CAGR (%), Market forecast (2023 - 2034)

1.2.2. Global Alpelisib Market Revenue Share (%) and Growth Rate (Y-o-Y) from 2019 - 2034

1.3.    Market Segmentation

1.3.1. Component of Global Alpelisib Market

1.3.2. Technology of Global Alpelisib Market

1.3.3. Distribution Channel of Global Alpelisib Market

1.3.4. Region of Global Alpelisib Market

2.      Executive Summary

2.1.    Global Alpelisib Market Industry Trends under COVID-19 Outbreak

2.1.1. Global COVID-19 Status Overview

2.1.2. Influence of COVID-19 Outbreak on Global Alpelisib Market Industry Development

2.2.    Market Dynamics

2.2.1. Drivers

2.2.2. Limitations

2.2.3. Opportunities

2.2.4. Impact Analysis of Drivers and Restraints

2.3.    Pricing Trends Analysis & Average Selling Prices (ASPs)

2.4.    Key Mergers & Acquisitions, Expansions, JVs, Funding / VCs, etc.

2.5.    Porter’s Five Forces Analysis

2.5.1. Bargaining Power of Suppliers

2.5.2. Bargaining Power of Buyers

2.5.3. Threat of Substitutes

2.5.4. Threat of New Entrants

2.5.5. Competitive Rivalry

2.6.    Value Chain / Ecosystem Analysis

2.7.    Russia-Ukraine War Impacts Analysis

2.8.    Economic Downturn Analysis

2.9.      Market Investment Opportunity Analysis (Top Investment Pockets), By Segments & By Region

3.      Global Alpelisib Market Estimates & Historical Trend Analysis (2019 - 2023)

4.      Global Alpelisib Market Estimates & Forecast Trend Analysis, by PRODUCT TYPE

4.1.    Global Alpelisib Market Revenue (US$ Mn) Estimates and Forecasts, by PRODUCT TYPE, 2019 to 2034

4.1.1. Piqray

4.1.2. Vijoyce

5.      Global Alpelisib Market Estimates & Forecast Trend Analysis, by Application

5.1.    Global Alpelisib Market Revenue (US$ Mn) Estimates and Forecasts, by Application, 2019 to 2034

5.1.1. Oncology

5.1.2. Breast cancer

5.1.3. Postmenopause

5.1.4. Others

6.      Global Alpelisib Market Estimates & Forecast Trend Analysis, by Distribution Channel

6.1.    Global Alpelisib Market Revenue (US$ Mn) Estimates and Forecasts, by Distribution Channel, 2019 to 2034

6.1.1. Drug Stores

6.1.2. Mail Order Pharmacies

6.1.3. Online

7.      Global Alpelisib Market Estimates & Forecast Trend Analysis, by Region

7.1.    Global Alpelisib Market Revenue (US$ Mn) Estimates and Forecasts, by Region, 2019 to 2034

7.1.1. North America

7.1.2. Europe

7.1.3. Asia Pacific

7.1.4. Middle East & Africa

7.1.5. South America

8.      North America Alpelisib Market: Estimates & Forecast Trend Analysis

8.1.    North America Alpelisib Market Assessments & Key Findings

8.1.1. North America Alpelisib Market Introduction

8.1.2. North America Alpelisib Market Size Estimates and Forecast (US$ Million) (2019 – 2034)

8.1.2.1.   By PRODUCT TYPE

8.1.2.2.   By Application

8.1.2.3.   By Distribution Channel

8.1.2.4.   By Country

8.1.2.4.1.     The U.S.

8.1.2.4.2.     Canada

8.1.2.4.3.     Mexico

9.      Europe Alpelisib Market: Estimates & Forecast Trend Analysis

9.1.    Europe Alpelisib Market Assessments & Key Findings

9.1.1. Europe Alpelisib Market Introduction

9.1.2. Europe Alpelisib Market Size Estimates and Forecast (US$ Million) (2019 – 2034)

9.1.2.1.   By PRODUCT TYPE

9.1.2.2.   By Application

9.1.2.3.   By Distribution Channel

9.1.2.4.        By Country

9.1.2.4.1.     Germany

9.1.2.4.2.     U.K.

9.1.2.4.3.     France

9.1.2.4.4.     Italy

9.1.2.4.5.     Spain

9.1.2.4.6.     Russia

9.1.2.4.7.     Rest of Europe

10.  Asia Pacific Alpelisib Market: Estimates & Forecast Trend Analysis

10.1.  Asia Pacific Market Assessments & Key Findings

10.1.1.   Asia Pacific Alpelisib Market Introduction

10.1.2.   Asia Pacific Alpelisib Market Size Estimates and Forecast (US$ Million) (2019 – 2034)

10.1.2.1.    By PRODUCT TYPE

10.1.2.2.    By Application

10.1.2.3.    By Distribution Channel

10.1.2.4.    By Country

10.1.2.4.1. China

10.1.2.4.2. Japan

10.1.2.4.3. India

10.1.2.4.4. Australia

10.1.2.4.5. South Korea

10.1.2.4.6. ASEAN

10.1.2.4.7. Rest of Asia Pacific

11.  Middle East & Africa Alpelisib Market: Estimates & Forecast Trend Analysis

11.1.  Middle East & Africa Market Assessments & Key Findings

11.1.1.   Middle East & Africa Alpelisib Market Introduction

11.1.2.   Middle East & Africa Alpelisib Market Size Estimates and Forecast (US$ Million) (2019 – 2034)

11.1.2.1.    By PRODUCT TYPE

11.1.2.2.    By Application

11.1.2.3.    By Distribution Channel

11.1.2.4.    By Country

11.1.2.4.1. U.A.E.

11.1.2.4.2. Saudi Arabia

11.1.2.4.3. Egypt

11.1.2.4.4. South Africa

11.1.2.4.5. Rest of Middle East & Africa

12.  South America Alpelisib Market: Estimates & Forecast Trend Analysis

12.1.  South America Market Assessments & Key Findings

12.1.1.   South America Alpelisib Market Introduction

12.1.2.   South America Alpelisib Market Size Estimates and Forecast (US$ Million) (2019 – 2034)

12.1.2.1.    By PRODUCT TYPE

12.1.2.2.    By Application

12.1.2.3.    By Distribution Channel

12.1.2.4.    By Country

12.1.2.4.1. Brazil

12.1.2.4.2. Argentina

12.1.2.4.3. Colombia

12.1.2.4.4. Rest of South America

13.  Competition Landscape

13.1.  Global Alpelisib Market Competition Matrix & Benchmarking, by Leading Players / Innovators / Emerging Players / New Entrants

13.2.  Global Alpelisib Market Competition White Space Analysis, By Distribution Channel

13.3.  Global Alpelisib Market Competition Heat Map Analysis, By Distribution Channel

13.4.  Global Alpelisib Market Concentration & Company Market Shares (%) Analysis, 2022

14.  Company Profiles

14.1.                     Novartis AG.

14.1.1.   Company Overview & Key Stats

14.1.2.   Financial Performance & KPIs

14.1.3.   Product Portfolio

14.1.4.   Business Strategy & Recent Developments

* Similar details would be provided for all the players mentioned below 

14.2.      Others

15.  Research Methodology

15.1.  External Transportations / Databases

15.2.  Internal Proprietary Database

15.3.  Primary Research

15.4.  Secondary Research

15.5.  Assumptions

15.6.  Limitations

15.7.  Report FAQs

16.  Research Findings & Conclusion